The company specializes in the R & D, production and sales of chemical preparations, the indications of which include nervous system, cardio-cerebrovascular, musculoskeletal, systemic anti-infection, anti-tumor, and regulation of water, electrolyte and acid-base balance, supplementary nutrition and other medical fields. The main products are oxiracetam injection, alanyl glutamine injection, brain protein hydrolysate for injection, ligustrazine hydrochloride for injection, osteopeptide for injection, Yanhuning for injection, mirtazapine tablets, valsartan dispersible tablets, glucose injection, sodium chloride injection and compound amino acid injection. In 2016, the company obtained the production license of medical devices and began to get involved in the research, development, production and sales of medical devices. at present, the company has obtained the production license of the second kind of medical device accessories and wound protection materials, and the main product is medical sodium hyaluronate repair paste.

(1) in order to strengthen the R & D capability, the company has constructed the R & D system with Sanlian Pharmaceutical Research Institute as the center, Sanlian Science and Technology, Methodist Science and Technology, Sanlian Pharmaceutical Engineering and Technology Research Center as the R & D platform, the synthetic drug pilot workshop, the oral disintegrating tablet pilot workshop and the oral solid preparation pilot workshop as the pilot platform, with more than 200 full-time R & D personnel. Among them, Sanlian Technology is mainly responsible for the topic selection and task distribution of the R & D project, as well as the research work, pilot test and pilot test of the oral solid preparation project; Methodist Technology is responsible for the research, small test and pilot test of the synthetic drug project; the Engineering Technology Research Center is mainly responsible for the research, small-scale and pilot-scale production of the liquid preparation project; the pilot workshop provides support for the pilot scale-up production of the R & D project.

(2) the company has a wide range of products, including nervous system, cardio-cerebrovascular, musculoskeletal, systemic anti-infection, anti-tumor, regulation of water, electrolyte and acid-base balance, supplementary nutrition and other medical fields. It has 140varieties and 219specifications of small volume injections, freeze-dried powder injections, solid preparations (including tablets, granules, capsules), large transfusions (including non-PVC soft bags, plastic bottles, glass bottles) and raw materials. Among them, 146 regulations are listed in the national medical insurance catalogue (including 64 in Class An and 82 in Class B), 43 in the National essential drugs catalogue and 81 in the Product regulations.

(3) the company's marketing center has set up more than 40 offices throughout the country and set up a high-quality marketing team of more than 300 people, which is responsible for market development, customer maintenance, product research and market information feedback. At the same time, through the fine management of the market according to the product category, it effectively expands the depth and breadth of the company's product market. The company's marketing is based on the market, providing customers with all-round pre-sale, in-sale and after-sales service to enhance customer adhesion. The company's large infusion sales market is mainly in Heilongjiang, Jilin and Inner Mongolia, accounting for more than 50% of the Heilongjiang market share. Large infusion has the characteristics of large usage and high unit weight, according to which the company has set up warehouses in Qiqihar, Jiamusi and Jixi, equipped with business personnel and internal staff, as well as distribution vehicles, in order to ensure drug storage and timely transportation in extreme rain and snow weather, and ensure the safety of drug use.